In a BSE filing, Natco Pharma announced "successful closure of inspection" with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.Natco Pharma gets EIR from USFDA for Hyderabad facility
In a BSE filing, Natco Pharma announced "successful closure of inspection" with the receipt of an establishment inspection report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad, India.
Subscribe to:
Post Comments (Atom)
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
The BRLLR linked to RBI Repo Rate is revised downwards in line with the reduction on Reserve Bank of India Repo Rate from 5.15 percent to 4...
-
Google has tried for years to get Samsung, the world#39;s leading mobile device maker by units sold, to drop its own services and give grea...
No comments:
Post a Comment